Department of Liver Transplantation, Cleveland Clinic Foundation, Cleveland, OH, USA.
Department of Transplantation, Oslo University Hospital, Oslo, Norway.
Ann Surg Oncol. 2024 Feb;31(2):697-700. doi: 10.1245/s10434-023-14611-z. Epub 2023 Nov 23.
Colorectal cancer is the second most common cause of cancer-related death worldwide, and half of patients present with colorectal liver metastasis (CRLM). Liver transplant (LT) has emerged as a treatment modality for otherwise unresectable CRLM. Since the publication of the Lebeck-Lee systematic review in 2022, additional evidence has come to light supporting LT for CRLM in highly selected patients. This includes reports of >10-year follow-up with over 80% survival rates in low-risk patients. As these updated reports have significantly changed our collective knowledge, this article is intended to serve as an update to the 2022 systematic review to include the most up-to-date evidence on the subject.
结直肠癌是全球癌症相关死亡的第二大主要原因，其中一半患者存在结直肠肝转移（CRLM）。肝移植（LT）已成为治疗无法切除的 CRLM 的一种治疗方式。自 2022 年 Lebeck-Lee 系统评价发表以来，更多的证据表明 LT 对高度选择的 CRLM 患者有效。其中包括低危患者超过 10 年随访，生存率超过 80%的报道。由于这些更新的报告显著改变了我们的集体知识，本文旨在对 2022 年的系统评价进行更新，纳入关于该主题的最新证据。
